<DOC>
	<DOC>NCT00174343</DOC>
	<brief_summary>To evaluate clinical and pathologic response rates following primary hormonal therapy by exemestane (AromasinÂ®)</brief_summary>
	<brief_title>Exemestane As Treatment In Neoadjuvant Setting For Operable Breast Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<criteria>Postmenopausal patients with unilateral breast cancer T2 to T4, N01, M0, non inflammatory, operable, hormonal receptors positive Patients with bilateral breast cancer T4d, inflammatory, non operable, hormonal receptors negative</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>